Skip to content

Oxidative stress, innate immune dysregulation and epigenetic characteristics of airway epithelium and airway smooth muscle in severe asthma

Oxidative stress, innate immune dysregulation and epigenetic characteristics of airway epithelium and airway smooth muscle in severe asthma

Status
Active, not recruiting
Phases
Early Phase 1
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2100052644
Enrollment
Unknown
Registered
2021-11-02
Start date
2022-01-01
Completion date
Unknown
Last updated
2023-04-12

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

asthma

Interventions

Severe asthma group:electronic bronchoscopy
Mild to moderate asthma group: electronic bronchoscopy
non-asthmatic control group: electronic bronchoscopy

Sponsors

The University of Hong Kong-Shenzhen Hospital
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: Severe asthma group: 1. Treatment situation: high-dose inhaled corticosteroids (ICS) or oral corticosteroids (OCS) (fluticasone > 1000mcg or equivalent), and another asthma control medication; 2. Asthma control: According to GINA guidelines, asthma is not controlled, and there are more than 3 of the following symptoms in the past 4 weeks: (1) Daytime symptoms >= 2 times/week; (2) Activities are restricted; (3) Nocturnal symptoms>=1/week; (4) The frequency of relief medication >= 2 times/week; (5) FEV1 = 2 times/year requiring high-dose oral corticosteroids, doubling the maintenance dose for more than 3 days or requiring hospitalization). 3. Asthma diagnosis: FEV1>=12% or absolute value >=200ml after inhalation of 400mcg salbutamol or presence of airway hyperresponsiveness or 2-day average PEF diurnal variation >8% or ICS, OCS, LABA and SABA FEV1 decreased by >= 12% and 200ml + history of recurrent asthma within 1 month during dose reduction. Mild to moderate asthma group 1. Treatment situation: low to moderate dose ICS ( 80% predicted value before using bronchodilator. 3. Partial asthma control: 1-2 of the following symptoms in the past 4 weeks: (1) Daytime symptoms >= 2 times/week; (2) Activities are restricted; (3) Nocturnal symptoms>=1/week; (4) The frequency of relief medication >= 2 times/week; (5) FEV1 =12% or absolute value >=200ml after inhalation of 400mcg salbutamol or presence of airway hyperresponsiveness or 2-day average PEF diurnal variation >8% or ICS, OCS, LABA and SABA FEV1 decreased by >= 12% and 200ml + history of recurrent asthma within 1 month during dose reduction. non-asthmatic control group 1. Treatment status: none; 2. Asthma control: FEV1>=80% predicted value in non-asthmatic patients; 3. Asthma diagnosis: no history of asthma, no history of other major diseases of the system.

Exclusion criteria

Exclusion criteria: 1. Current or previous smokers >10 years; 2. FEV1<1.0L after using bronchodilators; 3. Associated with other systemic serious diseases; 4. Contraindications for electronic bronchoscopy; 5. Unable to sign informed consent.

Design outcomes

Primary

MeasureTime frame
RNA;Protein;

Countries

China

Contacts

Public ContactRong Lei

The University of Hong Kong-Shenzhen Hospital

rongl@hku-szh.org+86 18818691792

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026